Similarly, in September 2020, the Ministry approved niraparib as a maintenance treatment for patients with newly diagnosed, platinum-sensitive epithelial ovarian cancer, regardless of BRCA1 or BRCA2 status. Here, BRCA2 is linked to ovarian carcinoma.